Skip to main content Skip to navigation Skip to search

ICE 2026

Poster Access

CAM2029 provides long-term and sustained biochemical control of acromegaly: ACROINNOVA 2 Phase 3 final analysis

CAM2029 maintains IGF-I and acromegaly symptom control across the 4-week dosing interval and intervals >28 days: data from ACROINNOVA 1

Patient‑reported outcomes following CAM2029 treatment for patients with acromegaly in the Phase 3 ACROINNOVA 2 trial